These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1141 related items for PubMed ID: 29082659

  • 21. Serum drug concentrations to optimize switching from adalimumab to etanercept in rheumatoid arthritis.
    L' Ami MJ, Ruwaard J, Krieckaert C, Nurmohamed MT, van Vollenhoven RF, Rispens T, Wolbink GJ.
    Scand J Rheumatol; 2019 Jul; 48(4):266-270. PubMed ID: 31012365
    [Abstract] [Full Text] [Related]

  • 22. Economic Burden of Switching to a Non-Tumor Necrosis Factor Inhibitor Versus a Tumor Necrosis Factor Inhibitor Biologic Therapy among Patients with Rheumatoid Arthritis.
    Zhou ZY, Griffith J, Du EX, Chin D, Betts KA, Ganguli A.
    Adv Ther; 2016 May; 33(5):807-23. PubMed ID: 27084724
    [Abstract] [Full Text] [Related]

  • 23. Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: post-hoc analyses from the GO-AFTER study.
    Smolen JS, Kay J, Matteson EL, Landewé R, Hsia EC, Xu S, Zhou Y, Doyle MK.
    Ann Rheum Dis; 2014 Oct; 73(10):1811-8. PubMed ID: 23897769
    [Abstract] [Full Text] [Related]

  • 24. Cost-utility analysis of certolizumab pegol in combination with methotrexate in patients with moderate-to-severe active rheumatoid arthritis in Greece.
    Tzanetakos C, Tzioufas A, Goules A, Kourlaba G, Theodoratou T, Christou P, Maniadakis N.
    Rheumatol Int; 2017 Sep; 37(9):1441-1452. PubMed ID: 28523420
    [Abstract] [Full Text] [Related]

  • 25. Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta-analysis of drug registries and health care databases.
    Souto A, Maneiro JR, Gómez-Reino JJ.
    Rheumatology (Oxford); 2016 Mar; 55(3):523-34. PubMed ID: 26490106
    [Abstract] [Full Text] [Related]

  • 26. The effect of extra-articular manifestations on tumor necrosis factor-α inhibitor treatment duration in patients with ankylosing spondylitis: nationwide data from the Korean College of Rheumatology BIOlogics (KOBIO) registry.
    Kim Y, Park S, Kim HS.
    Clin Rheumatol; 2018 Dec; 37(12):3275-3284. PubMed ID: 30251059
    [Abstract] [Full Text] [Related]

  • 27. Factors influencing the choice of first- and second-line biologic therapy for the treatment of rheumatoid arthritis: real-life data from the Italian LORHEN Registry.
    Monti S, Klersy C, Gorla R, Sarzi-Puttini P, Atzeni F, Pellerito R, Fusaro E, Paolazzi G, Rocchetta PA, Favalli EG, Marchesoni A, Caporali R.
    Clin Rheumatol; 2017 Apr; 36(4):753-761. PubMed ID: 28058538
    [Abstract] [Full Text] [Related]

  • 28. Retention rates of adalimumab, etanercept and infliximab as first and second-line biotherapy in patients with rheumatoid arthritis in daily practice.
    Frazier-Mironer A, Dougados M, Mariette X, Cantagrel A, Deschamps V, Flipo RM, Logeart I, Schaeverbeke T, Sibilia J, Le Loët X, Combe B.
    Joint Bone Spine; 2014 Jul; 81(4):352-9. PubMed ID: 24721422
    [Abstract] [Full Text] [Related]

  • 29. Treatment Persistence and Clinical Outcomes of Tumor Necrosis Factor Inhibitor Cycling or Switching to a New Mechanism of Action Therapy: Real-world Observational Study of Rheumatoid Arthritis Patients in the United States with Prior Tumor Necrosis Factor Inhibitor Therapy.
    Wei W, Knapp K, Wang L, Chen CI, Craig GL, Ferguson K, Schwartzman S.
    Adv Ther; 2017 Aug; 34(8):1936-1952. PubMed ID: 28674959
    [Abstract] [Full Text] [Related]

  • 30. Impact of biologic agents with and without concomitant methotrexate and at reduced doses in older rheumatoid arthritis patients.
    Zhang J, Xie F, Delzell E, Yun H, Lewis JD, Haynes K, Chen L, Beukelman T, Saag KG, Curtis JR.
    Arthritis Care Res (Hoboken); 2015 May; 67(5):624-32. PubMed ID: 25370912
    [Abstract] [Full Text] [Related]

  • 31. Treatment patterns among patients with rheumatic disease (rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA) and undifferentiated arthritis (UnA)) treated with subcutaneous TNF inhibitors.
    Tymms K, Littlejohn G, Griffiths H, de Jager J, Bird P, Joshua F, Nash P, Handel M, McManus H, Butcher BE, Youssef P.
    Clin Rheumatol; 2018 Jun; 37(6):1617-1623. PubMed ID: 29667098
    [Abstract] [Full Text] [Related]

  • 32. Retention rates of adalimumab, etanercept, and infliximab as first- or second-line biotherapies for spondyloarthritis patients in daily practice in Auvergne (France).
    Soubrier M, Pereira B, Fan A, Frayssac T, Couderc M, Malochet-Guinamand S, Mathieu S, Tatar Z, Tournadre A, Dubost JJ.
    Int J Rheum Dis; 2018 Nov; 21(11):1986-1992. PubMed ID: 30168265
    [Abstract] [Full Text] [Related]

  • 33. Risk of active tuberculosis in patients with inflammatory arthritis receiving TNF inhibitors: a look beyond the baseline tuberculosis screening protocol.
    Soare A, Gheorghiu AM, Aramă V, Bumbăcea D, Dobrotă R, Oneaţă R, Pintilie S, Milicescu M, Ancuţa I, Martin A, Sasu M, Ciofu C, Macovei L, Stoica V, Bojincă M, Mihai C.
    Clin Rheumatol; 2018 Sep; 37(9):2391-2397. PubMed ID: 29150737
    [Abstract] [Full Text] [Related]

  • 34. The role of concomitant methotrexate dosage and maintenance over time in the therapy of rheumatoid arthritis patients treated with adalimumab or etanercept: retrospective analysis of a local registry.
    Favalli EG, Becciolini A, Biggioggero M, Bertoldi I, Crotti C, Raimondo MG, Marchesoni A.
    Drug Des Devel Ther; 2018 Sep; 12():1421-1429. PubMed ID: 29872265
    [Abstract] [Full Text] [Related]

  • 35. Clinical response to golimumab in rheumatoid arthritis patients who were receiving etanercept or adalimumab: results of a multicenter active treatment study.
    Huffstutter JE, Kafka S, Brent LH, Matucci-Cerinic M, Tang KL, Chevrier M, Sprabery T, DeHoratius RJ.
    Curr Med Res Opin; 2017 Apr; 33(4):657-666. PubMed ID: 28035867
    [Abstract] [Full Text] [Related]

  • 36. Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study.
    Pappas DA, St John G, Etzel CJ, Fiore S, Blachley T, Kimura T, Punekar R, Emeanuru K, Choi J, Boklage S, Kremer JM.
    Ann Rheum Dis; 2021 Jan; 80(1):96-102. PubMed ID: 32719038
    [Abstract] [Full Text] [Related]

  • 37. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.
    Smolen JS, Kay J, Doyle MK, Landewé R, Matteson EL, Wollenhaupt J, Gaylis N, Murphy FT, Neal JS, Zhou Y, Visvanathan S, Hsia EC, Rahman MU, GO-AFTER study investigators.
    Lancet; 2009 Jul 18; 374(9685):210-21. PubMed ID: 19560810
    [Abstract] [Full Text] [Related]

  • 38. Comparison of the clinical effectiveness of tumour necrosis factor inhibitors and abatacept after insufficient response to tocilizumab in patients with rheumatoid arthritis.
    Akiyama M, Kaneko Y, Kondo H, Takeuchi T.
    Clin Rheumatol; 2016 Nov 18; 35(11):2829-2834. PubMed ID: 26971256
    [Abstract] [Full Text] [Related]

  • 39. Clinical Outcomes and Biologic Costs of Switching Between Tumor Necrosis Factor Inhibitors in US Veterans with Rheumatoid Arthritis.
    Cannon GW, DuVall SL, Haroldsen CL, Caplan L, Curtis JR, Michaud K, Mikuls TR, Reimold A, Collier DH, Joseph GJ, Harrison DJ, Sauer BC.
    Adv Ther; 2016 Aug 18; 33(8):1347-59. PubMed ID: 27352377
    [Abstract] [Full Text] [Related]

  • 40. Survival on treatment with second-line biologic therapy: a cohort study comparing cycling and swap strategies.
    Favalli EG, Biggioggero M, Marchesoni A, Meroni PL.
    Rheumatology (Oxford); 2014 Sep 18; 53(9):1664-8. PubMed ID: 24729445
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 58.